Efficacy and safety of first-line chemotherapies for patients with advanced pancreatic ductal adenocarcinoma: A systematic review and network meta-analysis
Background: Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease, often diagnosed at an advanced stage. Systemic chemotherapy is the primary treatment, but direct comparisons of different regimens are limited. This study conducted a systematic review and network meta-analysis (NMA) to compare...
Main Authors: | Mao-Ji Kang, Hao-Xin Li, Yu Gan, Cheng Fang, Xiao-Li Yang, Bo Li, Song Su |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2024-04-01
|
Series: | Heliyon |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2405844024037101 |
Similar Items
-
Adjuvant chemotherapy after surgery for pancreatic ductal adenocarcinoma: retrospective real-life data
by: Sophia Chikhladze, et al.
Published: (2019-11-01) -
[18F]FDG PET/MRI enables early chemotherapy response prediction in pancreatic ductal adenocarcinoma
by: Felix N. Harder, et al.
Published: (2021-07-01) -
An EMT-Related Gene Signature for Predicting Response to Adjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma
by: Zengyu Feng, et al.
Published: (2021-04-01) -
Metabolism remodeling in pancreatic ductal adenocarcinoma
by: Jin-Tao Li, et al.
Published: (2019-11-01) -
Oral mycobiota and pancreatic ductal adenocarcinoma
by: Ailin Wei, et al.
Published: (2022-12-01)